US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SATELLOS BIOSCIENCE INC.

7.30

+0.27003.84%

Post-market: 7.300.00000.00%17:10 EDT

Volume:47.43K

Turnover:337.98K

Market Cap:152.07M

PE:-4.03

High:7.45

Open:6.99

Low:6.82

Close:7.03

52wk High:13.39

52wk Low:5.50

Shares:20.83M

Float Shares:17.51M

Volume Ratio:2.11

T/O Rate:0.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8136

EPS(LYR):-1.7041

ROE:-50.74%

ROA:-31.38%

PB:2.15

PE(LYR):-4.28

Loading ...

Overview Company News Filings

Satellos to Participate in Upcoming Investor Conferences

Satellos resumed with a Speculative Buy at Canaccord

Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY

Press Release: Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc expected to post a loss of 69 cents a share - Earnings Preview

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Leerink Partners Initiates Satellos Bioscience at Outperform

MT Newswires Live

Satellos initiated with an Outperform at Leerink

Satellos Bioscience Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $20

THOMSON REUTERS

Press Release: Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Calendar of U.S. Earnings Expected in the Week Ahead

Cantor starts Satellos with an Overweight on DMD therapy potential

Satellos initiated with an Overweight at Cantor Fitzgerald

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:04 AM

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Satellos Bioscience Inc expected to post a loss of 8 cents a share - Earnings Preview

Oppenheimer Remains a Buy on Satellos Bioscience (MSLE)

Satellos Bioscience Inc : Oppenheimer Adjusts Target Price to $40 From $5 to Reflect 1-for-12 Reverse Stock Split

THOMSON REUTERS

Satellos Bioscience Completes $57.2 Million Public Offering

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSLE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSLE\",,,,,undefined,":{"symbol":"MSLE","market":"US","secType":"STK","nameCN":"SATELLOS BIOSCIENCE INC.","latestPrice":7.3,"timestamp":1780084800000,"preClose":7.03,"halted":0,"volume":47432,"hourTrading":{"tag":"盘后","latestPrice":7.3,"preClose":7.3,"latestTime":"17:10 EDT","volume":703,"amount":5146.9451,"timestamp":1780089022410,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03840682788051203,"floatShares":17510300,"shares":20831190,"eps":-1.813562,"marketStatus":"Market Closed","change":0.27,"latestTime":"05-29 16:00:00 EDT","open":6.99,"high":7.4499,"low":6.82,"amount":337983.973096,"amplitude":0.089602,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.813562,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.03,"postHourTrading":{"tag":"盘后","latestPrice":7.3,"preClose":7.3,"latestTime":"17:10 EDT","volume":703,"amount":5146.9451,"timestamp":1780089022410,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.1105840523107635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSLE\",,,,,undefined,":{"symbol":"MSLE","floatShares":17510300,"roa":"-31.38%","roe":"-50.74%","lyrEps":-1.704123,"volumeRatio":2.1105840523107635,"shares":20831190,"dividePrice":0,"high":7.4499,"amplitude":0.089602,"preClose":7.03,"low":6.82,"week52Low":5.5,"pbRate":"2.15","week52High":13.3949,"institutionHeld":0,"latestPrice":7.3,"eps":-1.813562,"divideRate":0,"volume":47432,"delay":0,"ttmEps":-1.813562,"open":6.99,"prevYearClose":12.5,"prevWeekClose":6.75,"prevMonthClose":7.95,"prevQuarterClose":5.63,"fiveDayClose":7.14,"twentyDayClose":7.95,"sixtyDayClose":12.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-15","symbol":"MSLE","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2026-03-27","symbol":"MSLE","fiscalQuarterEnding":"2025/12","expectedEps":-0.36,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-0.47},{"market":"US","date":"2026-02-06","symbol":"MSLE","reason":null,"defaultRemindTime":1770388200000,"announcedDate":"2026-02-05","type":"delisting","dateTimestamp":1770354000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MSLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1779336000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MSLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MSLE","date":"2026-05-29","current":-4.025228,"percent":0.868421,"low":-12.479818,"twenty":-10.770158,"median":-6.614029,"eighty":-5.255741,"high":-4.777882,"avg":-7.549182,"sd":2.409533,"marketCap":145462670.32},"quantilePoints":[{"date":"2026-02-13","current":-10.770362,"twenty":-10.948162,"median":-10.770362,"eighty":-10.650272,"marketCap":232264709.51},{"date":"2026-02-20","current":-10.655876,"twenty":-10.961105,"median":-10.795625,"eighty":-10.660269,"marketCap":229795787.77},{"date":"2026-02-27","current":-11.410036,"twenty":-11.040635,"median":-10.847134,"eighty":-10.698718,"marketCap":246059372.56},{"date":"2026-03-06","current":-11.830077,"twenty":-11.717077,"median":-10.918938,"eighty":-10.750564,"marketCap":255117626.85},{"date":"2026-03-13","current":-8.109914,"twenty":-11.50908,"median":-10.908981,"eighty":-10.660269,"marketCap":174891683.43},{"date":"2026-03-20","current":-7.707011,"twenty":-11.414276,"median":-10.795625,"eighty":-8.641353,"marketCap":166203013.02},{"date":"2026-03-27","current":-6.631132,"twenty":-11.347113,"median":-10.74587,"eighty":-7.112164,"marketCap":143001488.38},{"date":"2026-04-02","current":-5.025579,"twenty":-11.228066,"median":-10.659537,"eighty":-6.857362,"marketCap":125001211.63},{"date":"2026-04-10","current":-5.215911,"twenty":-11.093473,"median":-9.47912,"eighty":-5.796539,"marketCap":129735363.26},{"date":"2026-04-17","current":-7.29856,"twenty":-11.048776,"median":-7.908462,"eighty":-5.702641,"marketCap":181537079.31},{"date":"2026-04-24","current":-5.815307,"twenty":-10.982188,"median":-7.307008,"eighty":-5.899657,"marketCap":144644124.23},{"date":"2026-05-01","current":-6.614029,"twenty":-10.910972,"median":-7.101939,"eighty":-6.007657,"marketCap":164510727.14},{"date":"2026-05-08","current":-6.017774,"twenty":-10.898871,"median":-6.946772,"eighty":-6.020777,"marketCap":149680075.96},{"date":"2026-05-15","current":-6.08008,"twenty":-10.857436,"median":-6.796189,"eighty":-6.025643,"marketCap":151229840.1},{"date":"2026-05-22","current":-5.211571,"twenty":-10.78552,"median":-6.687256,"eighty":-5.618291,"marketCap":148529791.46},{"date":"2026-05-29","current":-5.103954,"twenty":-10.770158,"median":-6.614029,"eighty":-5.255741,"marketCap":145462670.32}],"updateTime":1780162051434},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSLE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638504934","title":"Satellos to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638504934","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638504934?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"TORONTO, May  27, 2026  (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)(“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301758/0/en/Satellos-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637933833","title":"Satellos resumed with a Speculative Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2637933833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637933833?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:18","pubTimestamp":1779362281,"startTime":"0","endTime":"0","summary":"Canaccord analyst Tania Armstrong-Whitworth resumed coverage of Satellos (MSLE) with a Speculative Buy rating and C$19 price target The company’s l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-resumed-with-a-speculative-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-resumed-with-a-speculative-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608618","title":"Satellos Bioscience Q1 EPS $(0.53) Down From $(0.44) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608618","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608618?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:09","pubTimestamp":1778843373,"startTime":"0","endTime":"0","summary":"Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.53) per share. This is a 20.45 percent decrease over losses of $(0.44) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52591899/satellos-bioscience-q1-eps-0-53-down-from-0-44-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPIQ","QQQM","QQQY","FTEC","JEPQ","SQQQ","MSLE","BK4139","PSQ","QID","QLD","QYLG","NDX","NVIW.SI","QDTE","QQQE","QQQJ","QQQA","TQQQ",".IXIC","NQmain","IYW","QQQ","TQQY","MNQmain","TECS","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635865350","title":"Press Release: Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635865350","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635865350?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":"-- Eleven clinical trial sites in BASECAMP currently active; remaining. -- BASECAMP remains on track to complete enrollment in Q3 2026. -- The Company has initiated the TRAILHEAD study in the U.S. in adults aged. -- Current cash available of $69.9M  provides runway through. \"The first quarter of 2026 was a productive time for Satellos. We raised $57M, providing runway to meet all planned milestones through the end of 2027, uplisted to Nasdaq, and advanced the Phase 2 TRAILHEAD and BASECAMP studies,\" said Frank Gleeson, MBA, Chief Executive Officer of Satellos. \"We are excited by the progress we are making with BASECAMP enrollment and dosing across 11 active clinical sites to date. We expect the additional sites intended to complete BASECAMP to be activated in Q2. We remain on track to complete BASECAMP enrollment in Q3 2026, supported by the active and planned sites currently having identified more than 100% of potential participants for screening and potential enrollment in the coming","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4097","BK4139","PRGS","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632617866","title":"Satellos Bioscience Inc  expected to post a loss of 69 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632617866","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632617866?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:10","pubTimestamp":1777641007,"startTime":"0","endTime":"0","summary":"Satellos Bioscience Inc  expected to post a loss of69cents a share - Earnings Preview Satellos Bioscience Inc MSCL.TO  is expected to  report resultson May 4 (estimated) for the period ending March 31","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186290","title":"Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186290","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186290?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"TORONTO, April  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)(“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270787/0/en/Satellos-to-Present-at-the-Bloom-Burton-Co-Healthcare-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4137","LU0128526141.USD","BK4581","BK4139","XBI","MSLE","BK4588","BK4585","LU0029874061.USD","LABU","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625679872","title":"Leerink Partners Initiates Satellos Bioscience at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2625679872","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625679872?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:50","pubTimestamp":1775476234,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Satellos Bioscience at Outperform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625751676","title":"Satellos initiated with an Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2625751676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625751676?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:41","pubTimestamp":1775472087,"startTime":"0","endTime":"0","summary":"Leerink initiated coverage of Satellos (MSLE) with an Outperform rating and $20 price target The firm believes Satellos represents a differentiated...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-initiated-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-initiated-with-an-outperform-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625737686","title":"Satellos Bioscience Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2625737686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625737686?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:09","pubTimestamp":1775470189,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P080:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622856823","title":"Press Release: Satellos Reports 2025 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2622856823","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622856823?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609200,"startTime":"0","endTime":"0","summary":"-- Completed a US$57.2 million equity financing; commenced trading on the. Nasdaq Global Market under the ticker \"MSLE\" on Feb. 6, 2026. -- Secured global regulatory clearances and initiated BASECAMP, a. placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to. less than 10 years living with Duchenne muscular dystrophy (\"Duchenne\" or. -- Presented initial functional outcomes from 56 days of treatment in. grip strength improvements observed in CL-101 were maintained or improved. in TRAILHEAD over an aggregate period of 9 to 13 months. -- Reported proteomic data from CL-101 (28-day Phase 1b trial in adults with. DMD) at MDA, showing reductions in established biomarkers of muscle. -- Presented validation of a Regenerative Index  biomarker at MDA,treatment and inform clinical interpretation; also presented new. BASECAMP is a global, randomized, placebo-controlled Phase 2 clinical trial in DMD evaluating safety, biomarkers and treatment effect of SAT-3247 over three months in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU0070302665.USD","LU2125154935.USD","LU1571399168.USD","LU2360032135.SGD","LU1599440770.SGD","LU1150488135.SGD","LU1941712348.USD","LU1675838814.USD","LU2463526074.USD","BK4018","LU0320765489.SGD","LU0985320562.USD","BK4504","SG9999001440.SGD","LU0731783394.SGD","LU1941712264.USD","LU0266013472.USD","LU1430594728.SGD","LU1150488218.USD","MDA","PRGS","BK4532","LU1236620750.USD","LU0345770308.USD","BK4588","BK4533","CL","BK4097","LU2065732104.USD","LU2125154778.USD","LU0323591593.USD","LU2108987350.USD","BK4139","MSLE","LU1585245621.USD","BK4187","BK4585","LU0208291251.USD","LU1236620834.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MKC.V","NMRA","HUMA","IMNN","KEEL","CCL","FC","LGN","BITF","ANGO","DEFT","NGEN","PLAY","ATOS","LW","RNXT","BEEM","BHST","INV","JILL","PENG","PRGS","NKLR","APOG","BYND","AUTL","INMB","BNZI","LNN","CRDL","MKC","BTBT","KOPN","AURA","MSLE","CALM","NEOG","NCNO","AIRJ","AEHR","BIRD","DMAC","AYI","NKE","KYTX","CAG","PHR","AIRO","FDS","MSM","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618944401","title":"Cantor starts Satellos with an Overweight on DMD therapy potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944401","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944401?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:00","pubTimestamp":1773230438,"startTime":"0","endTime":"0","summary":"As previously reported, Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Satellos (MSLE) with an Overweight rating and no price t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cantor-starts-satellos-with-an-overweight-on-dmd-therapy-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cantor-starts-satellos-with-an-overweight-on-dmd-therapy-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618466289","title":"Satellos initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2618466289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618466289?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:31","pubTimestamp":1773225101,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Satellos (MSLE) with an Overweight rating. Published first on TheFly – the ultimate source for real-time, m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/satellos-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/satellos-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618264956","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:04 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2618264956","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618264956?lang=en_us&edition=fundamental","pubTime":"2026-03-10 22:04","pubTimestamp":1773151474,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:04 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nAQN2LPKNU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618934221","title":"Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934221","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934221?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:00","pubTimestamp":1773140400,"startTime":"0","endTime":"0","summary":"Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvem","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252622/0/en/Satellos-Presents-Interim-SAT-3247-Clinical-and-Biomarker-Data-in-Duchenne-Muscular-Dystrophy-at-the-2026-MDA-Clinical-Scientific-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","SAT","BK4139","MDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617680825","title":"Satellos Bioscience Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680825","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680825?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:38","pubTimestamp":1772800700,"startTime":"0","endTime":"0","summary":"Satellos Bioscience Inc  expected to post a loss of8cents a share - Earnings Preview Satellos Bioscience Inc MSCL.TO  is expected to  report results on March 9 (estimated) for the period ending Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614209023","title":"Oppenheimer Remains a Buy on Satellos Bioscience (MSLE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614209023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614209023?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:56","pubTimestamp":1772117807,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Kostas Biliouris maintained a Buy rating on Satellos Bioscience yesterday and set a price target of $40.00. The company’s share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-satellos-bioscience-msle-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-satellos-bioscience-msle-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BK4139","BK4127","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610410623","title":"Satellos Bioscience Inc : Oppenheimer Adjusts Target Price to $40 From $5 to Reflect 1-for-12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2610410623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610410623?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:39","pubTimestamp":1770730759,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z616X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MSLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610158664","title":"Satellos Bioscience Completes $57.2 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2610158664","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610158664?lang=en_us&edition=fundamental","pubTime":"2026-02-10 06:41","pubTimestamp":1770676869,"startTime":"0","endTime":"0","summary":"Satellos Bioscience  said late Monday it has completed an underwritten public offering of approximately 5.2 million common shares, including an option for underwriters to buy an additional 712,574 common shares and in lieu of common shares for some investors, pre-funded warrants to buy 495,049 common shares.The common shares were sold at $10.10 a piece and the pre-funded warrants were sold at $10.09 a unit, the company said, with gross proceeds of approximately $57.2 million before accounting for underwriting discounts and commissions.The company said it plans to use the net proceeds from the offering to finance ongoing research and development activities, and for working capital and general corporate purposes.Franklin Berger, a member of Satellos' board, purchased 24,750 common shares in the offering, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}